Overview

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Status:
Not yet recruiting

Trial end date:
2023-12-18

Target enrollment:

Participant gender:

Summary

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab